About 14 results

Dr. Chiaka Anumudu at University of Ibadan previously identified 54 human proteins as potential biomarkers for schistosomiasis and bladder pathologies. Through WIPO Re:Search, Dr. Anumudu shared 60 urine samples with Dr. Horacio Bach at the University of British Columbia to support biomarker identification and validation. Upon identification of the biomarker(s), recombinant antibodies will be generated in Dr. Bach’s laboratory to develop a serological test for fast diagnosis.

An investigator at the University of Buea will share PCR products of two identified biomarker candidates to detect adult stage O. volvulus with a researcher at the University of British Columbia (UBC). The UBC researcher will express and share the recombinant antigens to test for the antibody response with the goal of developing a point-of-care, antibody-based diagnostic device with the novel ability to detect adult stage O. volvulus.

A UBC researcher will utilize his phage-display technology to develop new antibodies against Chagas disease host biomarkers identified by a McGill University researcher. Once developed, the antibody will be incorporated into the development of a diagnostic.

Takeda will provide a UBC researcher with a targeted set of compounds to screen against M. tuberculosis residing within macrophages.

GSK provided a UBC researcher with a set of compounds with different anti-malarial properties and clearance times. The UBC researcher tested the compounds’ effects on erythrocyte deformability during Plasmodium infection.

A McGill University researcher provided a UBC researcher with frozen cell extracts of Cryptosporidium infected cells. The UBC researcher used these extracts to identify potential antigens for use in a vaccine.

Drs. Pluschke and Scherr at the Swiss TPH were interested in repurposing tuberculosis drugs to treat Buruli ulcer, a bacterial infection caused by Mycobacterium ulcerans. BVGH connected Drs. Pluschke and Scherr with Drs. Thompson and Ramon-Garcia at UBC, who had discovered that certain avermectins showed promising activity against M. tuberculosis and other mycobacterial species. The UBC investigators shared eight avermectins with Drs. Pluschke and Scherr, who tested the compounds for their activity in an in vitro screen against clinical isolates of M. ulcerans.

A University of Lagos researcher provided a UBC researcher with serum, plasma, and urine samples from patients with severe malaria and asymptomatic malaria, as well as samples from healthy controls. The UBC researcher used proteomics to ascertain whether these samples had differing protein profiles, which could be used to identify biomarkers for a malaria diagnostic.

A UBC researcher elucidated the structures of ~10 natural products previously demonstrated by a University of Ibadan researcher to have anti-malarial or anti-tuberculosis activities.

A WEHI researcher provided a UBC researcher with recombinant P. vivax proteins involved in red blood cell entry. The UBC researcher used his phage display technology to produce antibodies against the proteins that were assessed for their ability to block P. vivax entry into red blood cells.